Navigation Links
CHMP Adopts Negative Opinion for ZEFTERA(TM)
Date:2/19/2010

BEERSE, Belgium, February 19, 2010 /PRNewswire-FirstCall/ --

- Cilag GmbH International to Terminate Collaboration

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.

Cilag GmbH International has given Basilea Pharmaceutica Ltd. notice of termination of the worldwide License , Development and Co-Promotion Agreement between the parties. The compound, including pending applications and in-market products, will be transitioned back to Basilea under the terms of the License Agreement.

Janssen-Cilag International NV and Cilag GmbH International are Johnson & Johnson companies.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Janssen-Cilag International NV and Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Neither Janssen-Cilag International NV nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

For further information, please contact: Media: Karen Manson - Office: +44-1737-644-690or Investor Relations: Stan Panasewicz - Office: +1-732-524-2524

SOURCE Janssen-Cilag International NV

Back to top
'/>"/>
SOURCE Janssen-Cilag International NV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech, Inc. Adopts Stockholder Rights Plan
2. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
3. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
4. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
5. SAFC Adopts Targeted Approach to Reach Pre-Registration
6. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
7. Gowlings Adopts RFID and Unifies Practice Management
8. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. Informed Medical Communications Adopts Newly Enhanced Compliance Policy
11. Atom Medical Adopts Masimo Rainbow SET Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The AMA is happy to announce that $48,000 in scholarships will be ... are created through funds donated by model aviation organizations and individuals, AMA members, and ... Scholarship Committee, which is made up of model aviation pilots and enthusiasts. The committee ...
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... ... 20, 2017 , ... Energetiq Technology , a world ... Chief Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI North ... connecting the electronics manufacturing supply chain. The mission of the SEMI NAAB is ...
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):